Sign inJoin waitlistJoin the waitlist

Peter Hosein

Clinical Research Lead · University of Miami/Jackson Health System

Credentials: · · · · ·

History

SCCC · University of Miami/Jackson Health System
Present
University of Miami/Jackson Health System
Present

Hematology and Medical Oncology
Jackson Memorial Hospital
2004–2007
Internal Medicine
Jackson Memorial Hospital
2001–2004
University of the West Indies Faculty of Medical Sciences
1997–2001

Research

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
Systematic review or meta-analysis · The Lancet Oncology · 2016 · 742 citations
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
Systematic review or meta-analysis · Journal of the National Cancer Institute · 2019 · 257 citations
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
BMC Cancer · 2012 · First of 12 authors · Corresponding · 183 citations

Jashodeep Datta
16 papers
Nipun Merchant
13 papers
Caio Lima
12 papers
Izidore Lossos
10 papers
Govindarajan Narayanan
7 papers
ED
Erin Dickey
6 papers
Jaime Merchan
6 papers
AL
Arturo Loaiza-Bonilla
5 papers
Alan Livingstone
4 papers
Caitlin Hester
4 papers
Daniel Sussman
4 papers
Dido Franceschi
4 papers

Clinical trials

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency
Principal investigator · Not yet recruiting · Phase 2
Peter Hosein, MD
2026–2031
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Principal investigator · Recruiting · Phase 1
Peter Hosein, MD
2025–2030
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
Principal investigator · Completed · Phase 1
Peter Hosein, MD
2023–2025
A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
Principal investigator · Terminated · Phase 1, Phase 2
University of Miami
2009–2014